Lunai Bioworks is able to completely regress both primary and metastatic pancreatic tumors in preclinical humanized models, representing a breakthrough in allogeneic cancer immunotherapy

Lunai Bioworks announces publication of second-generation allogeneic dendritic cell therapy platform in Vaccines. /PRNewswire/ — Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense…

Ginkgo Bioworks Issues Notice of Settlement of Shareholder Derivative Actions

, /PRNewswire/ –Ginkgo Bioworks (NYSE: DNA) today released the following notice: UNITED STATES DISTRICT COURTNORTHERN DISTRICT OF CALIFORNIAOAKLAND DIVISION WEINING HU, derivatively on behalf of…